The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Novartis; Pfizer
Research Funding - ARIAD (Inst); Bayer (Inst); Blueprint Medicines (Inst); Novartis (Inst); Pfizer (Inst)
 
Constance M Barysauskas
No Relationships to Disclose
 
Sarah Solomon
No Relationships to Disclose
 
Kadija Tahlil
No Relationships to Disclose
 
Rita Malley
No Relationships to Disclose
 
Melissa Hohos
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Travel, Accommodations, Expenses - Novartis (I)
 
Kathleen Polson
No Relationships to Disclose
 
Margaret Loucks
No Relationships to Disclose
 
Andrew J. Wagner
No Relationships to Disclose
 
Priscilla Merriam
No Relationships to Disclose
 
Jeffrey A. Morgan
No Relationships to Disclose
 
Scott J. Rodig
Honoraria - Bristol-Myers Squibb; Perkin Elmer
Consulting or Advisory Role - AstraZeneca; Perkin Elmer
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Patent pending for use of Anti-galectin1 antibodies for diagnostic use.
Travel, Accommodations, Expenses - Roche
 
F. Stephen Hodi
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck Sharp & Dohme; Novartis
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Geoffrey Shapiro
Consulting or Advisory Role - Chugai Pharma; G1 Therapeutics; Vertex
Research Funding - AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); Immune Design (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
George D. Demetri
Leadership - Blueprint Medicines
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; G1 Therapeutics; Kolltan Pharmaceuticals
Consulting or Advisory Role - ARIAD; Bayer; Daiichi Sankyo; EMD Serono; Genocea Biosciences; Janssen; Kyocera; Lilly; Nektar; Novartis; Pfizer; PharmaMar; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Abbvie; Bayer; Janssen; Novartis; Pfizer; PharmaMar
Patents, Royalties, Other Intellectual Property - Novartis